newsfilter
← Latest News
GlobeNewswire·

UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances

  • NeOnc Technologies Holdings appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors.
  • Alabedin brings over three decades of international banking & executive experience to support NeOnc's multinational clinical development & UAE expansion strategy.
  • CEO Amir F. Heshmatpour is scheduled to speak at the Abu Dhabi Future Health Summit 2026 on October 20–22 regarding capital, precision medicine, & international collaboration.
  • NeOnc holds investigational new drug authorizations from the Abu Dhabi Department of Health for both lead candidates, NEO100 & NEO212.
  • NEO100 received authorization for Phase 1 through Phase 2 adult protocols & pediatric studies, while NEO212 completed Phase 1 dose escalation & awaits Phase 2 ethics approvals.
  • August Phase 2a trial results for NEO100 reported 48.9% six-month progression-free survival & 26.09 months median overall survival in a 24-patient study.
  • The company priced a $15 million registered direct offering & saw insider open-market stock purchases following the clinical data release.
  • NeOnc redeemed all outstanding Series A convertible preferred stock to eliminate potential dilution without issuing common shares.
  • An FDA End-of-Phase 1 Type B meeting for NEO212 is scheduled for November 17 to discuss Phase 2 trial design & regulatory pathways.
  • The UAE partnership aims to leverage local infrastructure & regulatory frameworks to support global clinical development for central nervous system cancers.